ArchiveFebruary 2016

PoliticalSpeak & NewsSpeak: industry shenanigans

Pharma making things worse; the issue of high-cost drugs! #PoliticalSpeak #NewsSpeak #MSBlog #OffLabel “Do you think Pharma should be spending money on advertising to justify why they charge so much for their innovative drugs? Have your say and let’s continue the debate.” “Obviously, high-cost drugs and the reasons why they cost so much remains a political hot potato. We...

How to report epidemiology studies

Fiest KM, Marrie RA, Jette N, Bennett DA. The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis. Mult Scler. 2016 Feb 26. pii: 1352458516634873. [Epub ahead of print] BACKGROUND:Descriptive epidemiological studies documenting the incidence and prevalence of multiple sclerosis (MS) and studies that report morbidity, mortality, and economic...

Tolerability of Di Methyl Fumarate

Fox EJ, Vasquez A, Grainger W, Ma TS, von Hehn C, Walsh J, Li J, Zambrano J.Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).Int J MS Care. 2016 Jan-Feb;18(1):9-18. doi: 10.7224/1537-2073.2014-101 BACKGROUND: In phase 3 trials, delayed-release dimethyl fumarate (DMF; also...

ResearchSpeak: what have the leukodystrophies and MS in common?

I wonder how many PPMSers have been misdiagnosed? #ResearchSpeak #MSBlog #MSResearch “When I was still a ‘junior neurology consultant’ I made a spot diagnosis over the telephone that may have been life saving. One the lab technicians phoned me for advice. Her aunt who was in early 50’s with a diagnosis of PPMS and been admitted to her local hospital in ‘shock’...

Extending the Dose interval of natalizumab

Extended interval dosing of natalizumab in multiple sclerosis.Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM.J Neurol Neurosurg Psychiatry...

BrainHealth & ClinicSpeak: can the Brits really beat the Aussies?

How competitive are you when it comes to the health of your brain? #BrainHealth #ClinicSpeak #MSBlog #MSResearch “I have been banging ‘the holistic management of MS – brain health‘ drum for sometime now, hoping that the community will take the message seriously. If you repeat things enough people may start to say, yes I think this Giovannoni character is making a serious...

MS is Asia

Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA.Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review. Neuroepidemiology. 2016 ;46(3):209-221.  BACKGROUND: Multiple sclerosis (MS) is one of the most common chronic immune-mediated diseases of the human central nervous system and an important cause of non-traumatic neurologic...

ResearchSpeak: reply to an email from an expert PPMSer

Why shouldn’t MSers engage with drug development for progressive MS? #ResearchSpeak #MSBlog “The following is a personal email I received from a reader on the blog that I thought I should respond to via the blog as it has relevance to many people with PPMS.” Problem with sleeping, due to anxiety, so I thought I just drop you a line, that hopefully you can air about in your blog...

Collecting Stem Cells

Kyrcz-Krzemień S, Helbig G, Torba K, Koclęga A, Krawczyk-Kuliś M. Safety and efficacy of haematopoietic stem cells mobilization in patients with multiple sclerosis. Hematology. 2016 Feb. [Epub ahead of print] Introduction Multiple sclerosis (MS) is a T-cell-mediated chronic inflammatory disorder of the central nervous system. Several agents have been approved for treatment of MS...

Translate

Categories

Recent Posts

Recent Comments

Archives